Select Page

Group Psychotherapy Coupled with Psilocybin Shows Promise for Cancer Patients

Media Partners, Psychedelic News Wire

This post is presented by our media partner Psychedelic News Wire
View the original article here.

A recent study has found that psilocybin-assisted group psychotherapy can help alleviate the mental woes of cancer patients with depression. While several treatments are designed to kill cancer cells and alleviate the physical symptoms caused by cancer, the mental distress associated with a cancer diagnosis and treatment is rarely addressed.

Research shows that around 25% of people diagnosed with cancer suffer from depression. Cancer patients also deal with emotions such as anxiety, fear, sadness and grief, especially if they are diagnosed with particularly aggressive cancers. These psychological symptoms can cause cancer patients to become fatigued, withdrawn, lose interest in their preferred activities, and experience thinking and memory problems.

The recent study, whose findings were reported in the “Journal of Pain and Symptom Management,” shows that using psilocybin during group psychotherapy sessions may relieve some of these psychological symptoms.

Psychedelics represent a new and exciting frontier in the psychiatric field. A growing body of research has revealed that psychedelics may be able to treat various mental health disorders safely, effectively and with minimal side effects. Findings from preliminary studies have been so encouraging that institutions are investing millions of dollars into the development of psychedelic-based treatments for the mass market.

And with a significant portion of the American public currently dealing with conditions such as depression and PTSD with minimal relief from conventional treatments, psychedelics already have a large market desperate for effective therapies.

Prior studies have found that psilocybin, the main hallucinogenic agent in magic mushrooms, can be effective at treating major depressive disorder. Researchers from Johns Hopkins Medicine have found that psilocybin treatment can offer relief from depression for up to a year.

However, since most studies on the efficacy of psilocybin against depression over the long term have mostly focused on individual subjects, researchers wanted to see how the psychedelic acted in a group setting, especially in regard to an emotionally challenging and often isolating condition such as cancer. Assistant professor of psychiatry at the Huntsman Mental Health Institute at the University of Utah and study author Ben Lewis says that there are limited options for treating depression and anxiety symptoms in people diagnosed with cancer or terminal conditions.

He noted that while prior studies have provided promising results, the fact that they used individual format sessions makes access and scalability more challenging. Rather than studying individual models, Lewis’ team used a full-group model to test the efficacy, feasibility and safety of using psilocybin-assisted group therapy.

The team’s findings indicated that the group therapy was safe and well tolerated with no participants reporting any adverse effects other than from headache, hypertension and nausea in one patient. However, the researchers discovered that these symptoms were caused by viral gastroenteritis not psilocybin.

More about the therapeutic benefits of psychedelics is still being brought to light by psychedelics industry actors such as atai Life Sciences N.V. (NASDAQ: ATAI), so the world can look forward to more novel ways to use these substances for health and wellness purposes.

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text “Groovy” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published:

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
415.949.5050 Office

PsychedelicNewsWire is part of the InvestorBrandNetwork.

This post was originally published by our media partner here.